Chills

Lore & Background

Chills occur when the hypothalamic temperature set point is suddenly elevated due to causes such as tissue destruction, pyrogenic substances, or dehydration. Since the body temperature is below the new set point, mechanisms like vasoconstriction and shivering raise body temperature, causing the patient to feel cold even if their temperature is above normal. Once the new set point is reached, chills stop. If the elevating factor is removed, the set point decreases, triggering sweating and vasodilation in a phase called the 'crisis' or 'flush.'

Reader's Guide

Chills are a common symptom of fever and infection, reflecting the body's physiological response to reset its thermostat. The sensation of cold, even with elevated body temperature, is driven by prostaglandin E2 acting on the central amygdaloid nucleus via EP3 receptors, enhancing cold-sensory transmission. Understanding chills helps in managing febrile illnesses and distinguishing them from other causes of shivering, such as fear. The phenomenon underscores the complex interplay between immune signaling and thermoregulation.

Did You Know?

• Chills can occur without fever in specific people or from a scare.
• Severe chills with violent shivering are called rigors.
• Prostaglandin E2 induces warmth-seeking behavior in rats by enhancing cold-sensory transmission to the central amygdaloid nucleus.
• The phase of sweating and hot skin after chills is known as the 'crisis' or 'flush.'

The Acute Infection Phase

The initial wave of HIV infection strikes within days to weeks of exposure, manifesting in roughly half to nine-tenths of those infected. This primary phase typically runs for two to four weeks, averaging around fourteen to twenty-eight days, though in some cases symptoms can linger for months. The clinical picture closely mimics influenza or mononucleosis, presenting with fever, profound fatigue, swollen lymph nodes, a raw throat, skin rash, aching muscles, and sores in the mouth or esophagus. Less frequently, individuals report headaches, nausea, genital ulcers, an enlarged liver or spleen, unexplained weight loss, thrush, drenching night sweats, diarrhea, or even neurological disturbances. Because these manifestations are so nonspecific, clinicians frequently misattribute them to more common viral illnesses, and the symptoms are never used as a diagnostic criterion for HIV. Paradoxically, some of the most noticeable complaints—nasal congestion and sore throat—actually carry a sensitivity below the threshold of one minus specificity, meaning they are statistically more likely to appear in someone without HIV than in someone with it. Crucially, however, recognizing this phase matters enormously because the individual carries peak infectiousness during these early weeks.

The Latency and Chronic Phase

Once the immune system mounts a robust response, circulating viral particles drop sharply, ushering in what is termed the secondary or chronic stage. This interval is remarkably variable, spanning anywhere from a mere two weeks to two decades or beyond. During this period, HIV remains metabolically active within the lymph nodes, which often stay persistently enlarged as the virus becomes sequestered in the follicular dendritic cell network. Tissues densely populated with CD4+ T cells become secondary targets, and viral particles accumulate both inside infected cells and as free-floating virions. The CD4+ CD45RO+ memory T cell subset bears the heaviest proviral burden. Despite the apparent calm, individuals in this phase remain fully capable of transmitting the virus. A small minority of infected people—classified as long-term nonprogressors or elite controllers—sustain healthy CD4+ counts and, in the case of elite suppressors, maintain clinically undetectable viral loads entirely without antiretroviral therapy. For the overwhelming majority, however, detectable viremia persists, and without treatment the infection will inexorably march toward the AIDS stage.

The AIDS Stage and Its Consequences

AIDS represents the terminal clinical expression of HIV, formally defined when CD4+ T cell counts fall below two hundred cells per microliter of blood. At this point, the immune architecture has deteriorated so severely that organisms normally kept in check—bacteria, viruses, fungi, and parasites—exploit the breach and produce opportunistic infections that can strike virtually every organ system. The declining ratio of CD4+ to CD8+ cells serves as a reliable harbinger of this progression. Beyond infections, individuals with AIDS face a markedly elevated risk of specific malignancies, including Kaposi's sarcoma, cervical cancer, and lymphomas of the immune system. Systemic complaints such as persistent fevers, drenching night sweats, chronically swollen glands, chills, progressive weakness, and significant weight loss are common hallmarks. Importantly, the particular opportunistic infections a patient develops are not universal; they are shaped in part by which pathogens are most prevalent in the geographic region where the individual lives, making the clinical presentation a function of both immunology and local epidemiology.

Pulmonary Threats and Global Disparities

Two pulmonary conditions dominate the HIV-associated disease landscape. Pneumocystis pneumonia, caused by the fungus Pneumocystis jirovecii, is rare in immunocompetent individuals yet was once a leading immediate cause of death among HIV patients in Western nations before effective prophylaxis became standard. In developing regions, it still frequently serves as the first clinical clue to AIDS in previously untested patients, typically emerging only when CD4 counts dip below two hundred. Tuberculosis occupies a uniquely dangerous niche: unlike most HIV-associated infections, it spreads through the air to healthy people, and multidrug-resistant strains pose a severe treatment challenge. The World Health Organization has flagged TB/HIV co-infection as a major global health crisis; in 2007 alone, four hundred fifty-six thousand deaths among new TB cases involved HIV positivity, accounting for a third of all TB fatalities and nearly a quarter of the estimated two million HIV-related deaths that year. While directly observed therapy has curbed incidence in wealthier nations, the burden in regions where HIV is most concentrated remains stubbornly high. In early HIV, TB presents as a straightforward lung disease, but in advanced infection it frequently takes an atypical, extrapulmonary form, scattering through bone, the urinary and gastrointestinal tracts, the liver, lymph nodes, and the central nervous system.

Gallery